ATXI News and Press, Avenue Therapeutics Inc. From 12/01/23

MIAMI, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced tha...

2023-11-29 10:02:31 ET DENVER, Colo., Nov. 29, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Vivos Therapeutics Inc (NASDAQ: VVOS), Rover Group Inc (NASDAQ: ROVR), Redhill Biopharma Ltd (NASDAQ: RDHL), ...

2023-11-14 01:52:35 ET More on Avenue Therapeutics Avenue Therapeutics stock plummets on pricing of 16.6M units at $0.3006 in public offering Avenue Therapeutics drops 6% on proposed equity offering Seeking Alpha’s Quant Rating on Avenue Therapeutics H...

- Phase 1b/2a clinical trial of AJ201 remains on track to report topline data in second quarter of 2024 - - Positive BAER-101 preclinical data accepted for presentation at American Epilepsy Society (AES) Annual Meeting - - Agreement reached with U.S. FDA on study design and anal...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

Avenue Therapeutics Inc. (ATXI) is expected to report for Q1 2024

MIAMI, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the...

2023-10-31 09:32:50 ET More on Avenue Therapeutics, Fortress Biotech, etc. Fortress Biotech CEO acquires 100,000 company shares Avenue Therapeutics drops 6% on proposed equity offering Seeking Alpha’s Quant Rating on Avenue Therapeutics Historical earn...

MIAMI, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the...

2023-09-19 00:56:57 ET More on Avenue Therapeutics Seeking Alpha’s Quant Rating on Avenue Therapeutics Historical earnings data for Avenue Therapeutics Financial information for Avenue Therapeutics For further details see: Avenue Therapeutics drops...